New York: Adamis Pharma (NASDAQ:ADMP) Stock Has Just Had Its Buy Rating Reiterated by Raymond James. Shares now Have a $7.0 Target

March 19, 2018 - By Adrian Erickson

 New York: Adamis Pharma (NASDAQ:ADMP) Stock Has Just Had Its Buy Rating Reiterated by Raymond James. Shares now Have a $7.0 Target

Adamis Pharma (NASDAQ:ADMP) Rating Reaffirmed

Raymond James now has a $7.0 target price per share on the $128.55M market cap company or 81.82 % upside potential. In analysts report issued on Monday, 4 December, Adamis Pharma (NASDAQ:ADMP) shares have had their Buy Rating maintained by analysts at Raymond James.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma has $16 highest and $5 lowest target. $9.75’s average target is 153.25% above currents $3.85 stock price. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 21 by Maxim Group. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Thursday, July 21 with “Buy” rating. The stock has “Buy” rating by Maxim Group on Monday, June 12. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) earned “Buy” rating by Raymond James on Monday, December 4. As per Tuesday, December 1, the company rating was initiated by Maxim Group. Raymond James initiated the shares of ADMP in report on Tuesday, September 12 with “Buy” rating.

The stock increased 2.67% or $0.1 during the last trading session, reaching $3.85. About 878,185 shares traded or 8.83% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since March 19, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Analysts await Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report earnings on March, 29.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $128.55 million. The company's specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: